Acute kidney injury (AKI) is a serious clinical syndrome with high morbidity, elevated
mortality, and poor prognosis, commonly considered a “sword of Damocles” for hospitalized …

Currently, there are no clinical drugs available to treat acute kidney injury (AKI). Given the
high prevalence and high mortality rate of AKI, the development of drugs to effectively treat …

Fibrosis is an excessive accumulation of extracellular matrix (ECM) that may cause severe
organ dysfunction. Nitric oxide (NO), a multifunctional gaseous signaling molecule, may …

Drug-induced acute kidney injury (DI-AKI) presents a substantial clinical challenge with
limited therapeutic options. This study investigate the potential of arginase-2 (Arg-2) as a …

Acute kidney injury (AKI) has been a global public health concern leading to high patient
morbidity and mortality in the world. Nanotechnology-mediated antioxidative therapy has …

Idiopathic pulmonary fibrosis (IPF) is a progressive pulmonary disease that leads to
interstitial inflammation, lung damage, and eventually life-threatening complications. Among …

Acute kidney injury (AKI) is a pathological process with high morbidity, and drug resistance
is easy to occur due to untargeted drug therapy. Curcumin can repair acute kidney injury …

Current management of anesthesia‐associated complications falls short in terms of both
efficacy and safety. Nanomaterials with versatile properties and unique nano‐bio …

Acute kidney injury (AKI) is a clinical syndrome that results from a rapid decline in renal
structure or renal functional impairment with the main pathological feature of sublethal and …

Combination therapy targeting multiple therapeutic targets is a favorable strategy to achieve
better therapeutic outcomes in cancer and inflammatory diseases. Codelivery is a subfield of …